Vera Therapeutics (VERA) Operating Expenses (2020 - 2026)

Vera Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $125.1 million for Q1 2026.

• Quarterly Operating Expenses rose 118.79% year-over-year to $125.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $383.4 million (up 98.4% YoY) and the FY2025 annual result came in at $315.5 million, up 88.71% from the prior year.
• Operating Expenses was $125.1 million for Q1 2026 at Vera Therapeutics, up from $94.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $125.1 million in Q1 2026 and bottomed at $15.1 million in Q2 2022.
• A 5-year average of $47.1 million and a median of $33.6 million in 2022 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 260.92% — and 2023, when it decreased 19.51%.
• Vera Therapeutics' Operating Expenses stood at $33.6 million in 2022, then decreased by 19.51% to $27.0 million in 2023, then surged by 80.98% to $48.9 million in 2024, then surged by 92.6% to $94.2 million in 2025, then soared by 32.83% to $125.1 million in 2026.
• Business Quant data shows VERA's Operating Expenses at $125.1 million in Q1 2026, $94.2 million in Q4 2025, and $83.9 million in Q3 2025.